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High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for
metastatic melanoma, but the efficacy and safety of the combination are unknown. The
objective of this study was to evaluate the feasibility, safety, and efficacy of combination
high-dose IPI and high-dose IL-2 in patients with histologically confirmed advanced
unresectable stage III and IV melanoma. This Phase II, multicenter, open-label, single-arm
trial was conducted in nine patients enrolled between 12/2014 and 12/2015. Subjects
were treated with high-dose IPI 10 mg/kg intravenous (IV) every 3 weeks for four
doses starting at week 1 and high-dose IL-2 (600,000 IU/kg IV bolus every 8 h for
up to 14 doses) concurrently with IPI at weeks 4 and 7. After the first 12 weeks of
combination therapy, maintenance IPI (10 mg/kg IV) monotherapy was administered
every 12 weeks for up to 1 year. No patient had received prior PD-1 blockade, and only
one received prior vemurafenib. Confirmed partial response was achieved in one (11%),
stable disease in four (44%), and progressive disease in four (44%) of nine patients. Two
patients achieved durable disease control of 44+ and 50+ months at the most recent
follow-up without subsequent therapy. The median overall survival was not reached after
a minimum 24 months of follow-up time. One-year and 2-year survival rates were 89
and 67%, respectively. Seven patients (78%) experienced grade 3 or 4 adverse events
related to the study therapy, three of which were attributed to both agents. One patient
discontinued the treatment due to liver and kidney toxicity. While toxicity was significant,
all events were reversible, and there was no treatment-related mortality. In peripheral
blood of patients with decreasing tumor burden, the ratio of the non-classical MHC-II
proteins HLA-DM to HLA-DO increased 2-fold, raising the possibility of the ratio of
HLA-DM:HLA-DO as a novel biomarker of response to treatment. Although the sample
size was limited, combination therapy with high-dose IPI and high-dose IL-2 was feasible
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and associated with clinical benefit. IL-2-based compounds in combination with CTLA-
4 blockade should be studied in advanced melanoma patients who fail to benefit from
first-line PD-1 blockade.
Clinical Trial Registration: ClinicalTrials.gov, NCT02203604. Registered 30 July
2014, https://clinicaltrials.gov/ct2/show/NCT02203604.
Keywords: melanoma, interleukin-2, cytokine, ipilimumab, combination immunotherapy, hepatitis, antigen
presentation
INTRODUCTION
The cytotoxic T lymphocyte antigen 4 (CTLA-4) checkpoint
inhibitor, ipilimumab (IPI), which sustains T cell activity by
blocking T cell response inhibition, is associated with a 15–
20% response rate in melanoma patients (1) and with long-
term progression-free survival of 21% (2). High-dose interleukin-
2 (IL-2) administered as first-line therapy for patients with
advanced melanoma results in a response rate of 15–20%, of
which approximately one-third are durable complete responses
(CRs) sometimes lasting for decades (3). High-grade but short-
lived toxicities necessitate inpatient administration and have
limited the widespread use of IL-2, but it can be delivered safely
in experienced centers with appropriate supportive care (4–6).
The role of high-dose IL-2 in subsequent lines of therapy for
patients treated with first-line PD-1 antibody (pembrolizumab
or nivolumab) is less clear, but retrospective, pooled datasets
have suggested similar activity for high-dose IL-2 in this
setting (7). CTLA-4 is expressed after T cell activation, and
blocking this inhibitory signal while driving T cell proliferation,
differentiation, and cytotoxicity with IL-2 is a rational treatment
strategy. In fact, a phase I/II trial of IPI followed by IL-2 has
previously been conducted, but with IPI doses only up to 2
mg/kg (8, 9). Responses were observed in eight of 36 (22%)
patients (including 6 CRs). Five of 36 (14%) patients developed
grade 3–4 IPI-related toxicities, but all were reversible. High-
dose IPI (10 mg/kg) is significantly more effective than 3 mg/kg
(HR for OS = 0.84, 95% CI 0.70–0.99, p = 0.04), but it is also
more toxic, with grade 3–4 diarrhea in 10% and colitis in 5% of
patients (10). Therefore, we conducted a trial to determine the
feasibility, efficacy, and safety of combination high-dose IPI and
high-dose IL-2 in patients with metastatic melanoma. We chose
the sequence of IPI followed by IL-2 based on our hypothesis
that IPI could prevent T cell exhaustion induced by IL-2-driven
T cell proliferation.
METHODS
Patient Selection
Adults with histologically confirmed unresectable stage III and
IV melanoma and ECOG performance status 0–1 were enrolled
at Rutgers Cancer Institute of New Jersey and Providence
Cancer Institute. Main exclusion criteria were primary
Abbreviations: IPI, ipilimumab; IL-2, interleukin-2; IV, intravenous; CTLA-4,
cytotoxic T lymphocyte antigen 4; CR, complete response; PBMC, peripheral blood
mononuclear cell.
ocular, active brain metastases, active autoimmune disease,
concurrent systemic immunosuppressive therapy, significant
cardiopulmonary disease, and organ dysfunction. Patients
with prior treatment with IPI or IL-2 were excluded. Prior
PD-1-directed therapy and BRAF-directed therapy was allowed.
Design
This was a single-arm study with a primary endpoint of objective
response rate in the first 24 weeks of treatment, reported with a
95% confidence interval (CI). The protocol (CINJ#091309) was
approved by institutional IRBs and registered (NCT02203604).
All patients gave written informed consent. Secondary endpoints
included safety, feasibility, overall survival, 1- and 2-year survival,
progression-free survival, and best overall response. The planned
target sample size was up to 82 patients, but the sponsor stopped
the trial early due to slow enrollment.
Treatment
All patients received induction with IPI (10 mg/kg IV every
3 weeks for four doses) starting at Week 1. At weeks 4 and
7, patients also received high-dose IL-2 (600,000 IU/kg IV
bolus every 8 h for up to 14 doses, as tolerated) immediately
following IPI. IL-2 dose was calculated using actual body weight,
although adjustment to ideal body weight for obese patients
was allowed. Following IPI induction, maintenance IPI (10
mg/kg IV) was administered every 12 weeks for four doses.
Dose reductions were not permitted for either drug. Both drugs
were held and/or discontinued for severe autoimmune toxicity.
A physical examination and laboratory tests (including CBC
with differential and comprehensive metabolic profile, including
liver function and thyroid tests) were done at screening and
every 3 weeks. Safety assessments were performed daily during
hospitalization for IL-2 therapy. Imaging for tumor assessments
was performed every 12 weeks. Response was assessed using
WHO criteria modified for immune-related response (11).
Adverse events (AEs) were evaluated and graded using NCI
Common Toxicity Criteria v4.0.
Immune Studies and Statistical Analysis
Blood was collected at weeks 1, 4, 7, 12, and 24. Serum
was analyzed for cytokines using the LEGENDPlex human
CD8/NK panel (BioLegend), and peripheral blood mononuclear
cells (PBMCs) were analyzed using flow cytometry. For
intracellular measurement of HLA-DM and HLA-DO levels,
samples were incubated with antibodies to identify peripheral
B cells (CD45+ CD19+ MHC-II+), fixed and permeabilized
with Cytofix/Cytoperm (BD PharMingen), and stained with
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antibodies specific for HLA-D (12) and HLA-DO (13). Ratios
of the non-classical MHC-II proteins, HLA-DM, and HLA-
DO, are a novel marker of antigen presentation potential
and was obtained by dividing the mean fluorescent intensity
levels obtained for HLA-DM by that obtained for HLA-DO
(14, 15). Levels were compared in patients with decreasing
vs. increasing tumor burden using two-way ANOVA with
Bonferroni correction for multiple comparisons. Descriptive
statistics were used for clinical outcome and safety reporting.
RESULTS
Patient Characteristics and Treatment
Delivery
Although the trial was stopped in May 2016 due to
discontinuation of funding, the safety and efficacy of treatment
for nine patients enrolled betweenDecember 2014 andDecember
2015 are reported (Figure 1). Baseline patient characteristics
are summarized in Table 1. Four patients with cutaneous, four
with acral, and one with anal mucosal primary melanoma were
enrolled. All patients had an ECOG performance status of 0.
No patients received anti-PD-1 prior to enrolling. Two patients
had received adjuvant interferon, and one received vemurafenib
in the metastatic setting. Patients received a median of four
IPI (range, 2–7) and 11 IL-2 (range, 3–18) doses. No patients
received more than two cycles (one course) of IL-2.
Safety
There were no treatment-related deaths. Seven of nine patients
(78%) experienced a grade 3 or 4 treatment-related adverse event
(AE), three of which were attributed to both agents (Table 2).
The most frequent grade 3 and 4 AEs were liver and kidney
injury, which occurred during the first 12 weeks of therapy in four
patients. One patient experienced grade 4 hyperbilirubinemia,
grade 3 transaminase elevation, and grade 4 acute kidney
injury during the first cycle of combination high-dose IL-
2 and high-dose IPI. The patient was given corticosteroids,
and liver and kidney injury resolved 1 month later. The
patient was removed from the study due to unacceptable
toxicity. Another patient experienced grade 3 transaminase
elevation, hyponatremia, and hypotension related to both agents.
Approximately 2 weeks after discontinuation of high-dose IL-
2, the transaminases rose to grade 4 and the patient required
corticosteroid and mycophenolate mofetil for 2 months before
the hepatitis resolved. A third patient had grade 4 hematologic
toxicity, grade 3 anemia, grade 4 thrombocytopenia, and grade 3
acute kidney injury after the second cycle of combination high-
dose IL-2 and high-dose IPI. A bone marrow biopsy showed
adequate megakaryocytes, and the patient was treated with
steroids for autoimmune thrombocytopenia for ∼1 month with
eventual resolution of platelet count. A fourth patient had grade
4 transaminase elevation during the first 12 weeks that was
attributed only to IPI. This patient improvedwithout steroids and
went on to complete 1 year of study therapy with maintenance
IPI. Colitis and serious diarrhea were not observed. Grade 1 and
2 diarrhea was noted in four and one patients, respectively.
Efficacy
Best overall response by week 24 was partial response in one
patient (11%; 95% CI 0.57–43.5%) and stable disease in four
patients (44%), with progressive disease in four patients (44%;
Figure 2). Minimum follow-up time was 24 months. The median
FIGURE 1 | CONSORT flow diagram demonstrates the flow of subjects throughout the study.
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TABLE 1 | Baseline characteristics of patients treated.
Age (median years and range) 52.5 (25.0–65.6)
Gender
Male 5 (56%)
Female 4 (44%)
Race
Caucasian 9 (100%)
Ethnicity
Non-Hispanic 6 (67%)
Hispanic 3 (33%)
ECOG PS
0 9 (100%)
Prior treatment
Any 3 (33%)
Adjuvant interferon 2 (22%)
Targeted therapy (vemurafenib) 1 (11%)
Stage (AJCC 7th)
IIIC, unresectable 1 (11%)
IV 8 (89%)
Primary site
Cutaneous 4 (44%)
Acral 4 (44%)
Mucosal 1 (11%)
OS was not reached, with 1- and 2-year OS rates of 89 and
67%, respectively. Six patients received post-study therapy for
progressive disease, most commonly PD-1-directed checkpoint
blockade. The patient with the partial response was a 53-year-
old woman with a cutaneous primary melanoma of the lower
extremity, who experienced an 74% reduction in tumor burden
at week 24. Her response was ongoing at 50.0 months of follow-
up without subsequent therapy. A patient with stable disease had
clear clinical benefit not meeting response criteria. This patient
was a 50-year-old man with acral melanoma of the toe web, who
experienced a 30% reduction in tumor burden at week 24 and
continues without progression at 44.2 months of follow-up.
Immune Responses
Patients were divided based on response, specifically increased
vs. decreased tumor burden. Granzyme B, a marker of cytolytic
potential, and HLA-DM:HLA-DO ratio, a marker of antigen
presentation capability (14, 15), were significantly increased in
patients with decreased tumor burden at weeks 12–24 (Figure 3).
No differences were observed in CD8+ effector or CD4+
regulatory T cells (data not shown).
DISCUSSION
The therapeutic landscape for melanoma has changed
dramatically over the past decade, with 11 new agents approved
since 2011 (16). This inlcudes multiple small molecule inhibitors
of the MAPK pathway and three immune checkpoint inhibtiors.
Yet, many patients do not respond to treatment or develop
secondary resistance after exposure to individual agents and/or
TABLE 2 | Frequency of treatment-related adverse events (AEs).
System All grades Grade 1 Grade 2 Grade 3 Grade 4
(A)
Cardiovascular 5 (56%) 2 (22%) 3 (33%) 4 (44%) 0 (0%)
Eye 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Gastrointestinal 8 (89%) 7 (78%) 4 (44%) 3 (33%) 1 (11%)
General/constitutional 6 (67%) 6 (67%) 2 (22%) 1 (11%) 0 (0%)
Hematologic 2 (22%) 2 (22%) 1 (11%) 1 (11%) 1 (11%)
Infectious 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Metabolic/nutritional 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Musculoskeletal 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Psychiatric 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pulmonary 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Renal/electrolyte 7 (78%) 3 (33%) 2 (22%) 6 (67%) 1 (11%)
Skin 5 (56%) 4 (44%) 3 (33%) 0 (0%) 0 (0%)
Any 9 (100%) 8 (89%) 8 (89%) 7 (78%) 2 (22%)
(B)
Cardiovascular 1 (11%) 0 (0%) 1 (11%) 1 (11%) 0 (0%)
Eye 1 (11%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Gastrointestinal 7 (78%) 6 (67%) 4 (44%) 3 (33%) 3 (33%)
General/constitutional 5 (56%) 3 (33%) 3 (33%) 0 (0%) 0 (0%)
Hematologic 2 (22%) 2 (22%) 2 (22%) 1 (11%) 1 (11%)
Infectious 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Metabolic/nutritional 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Musculoskeletal 1 (11%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Psychiatric 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pulmonary 1 (11%) 1 (11%) 0 (0%) 0 (0%) 0 (0%)
Renal/electrolyte 3 (33%) 1 (11%) 1 (11%) 3 (33%) 1 (11%)
Skin 6 (66%) 5 (56%) 4 (44%) 0 (0%) 0 (0%)
Any 9 (100%) 8 (89%) 6 (67%) 4 (44%) 4 (44%)
(C)
Cardiovascular 1 (11%) 0 (0%) 1 (11%) 1 (11%) 0 (0%)
Eye 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Gastrointestinal 5 (56%) 4 (44%) 2 (22%) 2 (22%) 1 (11%)
General/constitutional 4 (44%) 3 (33%) 2 (22%) 0 (0%) 0 (0%)
Hematologic 1 (11%) 1 (11%) 1 (11%) 1 (11%) 1 (11%)
Infectious 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Metabolic/nutritional 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Musculoskeletal 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Psychiatric 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pulmonary 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Renal/electrolyte 3 (33%) 1 (11%) 1 (11%) 3 (33%) 1 (11%)
Skin 4 (44%) 3 (33%) 3 (33%) 0 (0%) 0 (0%)
Any 7 (78%) 7 (78%) 5 (56%) 3 (33%) 2 (22%)
Number of subjects (%) with AEs related to (A) high-dose IL-2, (B) high-dose IPI, or (C)
combination high-dose IPI and high-dose IL-2.
regimens. The potential to improve responses by combination
treatment with two agents has emerged as a major area of
clinical investigation, and has been largely supported by
an improvement in clinical outcomes for combination IPI
and nivolumab, although this regimen has been associated
with significant toxicity (17). Since combination of approved
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melanoma agents is now a high priority, we sought to determine
the feasibility, safety, and initial response rate of high-dose IPI
and high-dose IL-2.
Combination high-dose IPI and high-dose IL-2 treatment
was associated with significant AEs, including grade 3–4 AEs in
seven of nine patients (78%). There were no new safety signals
observed; however, expected IL-2-related side effects such as liver
and kidney injury were more prolonged than usual, and systemic
corticosteroids were required to treat immune related adverse
events in three patients. There was no mortality and surprisingly,
no serious diarrhea or colitis was observed. We did confirm the
feasibility of combination high-doses IPI and high-dose IL-2, but
our results are limited by the small sample size due to loss of
FIGURE 2 | Waterfall plot of best overall response by week 24 for individual
metastatic melanoma patients treated with high-dose IPI and high-dose IL-2.
Bars represent the best overall response by week 24 as a percent change in
tumor burden for each treated patient. Red bars denote patents with increased
tumor burden, and green bars denote patients with decreased tumor burden.
funding and premature closure of the study. Of the nine patients
who received treatment, there was only 1 responder. Two patients
were alive without disease progression after 44+ and 50+months
without subsequent therapy. These durable responses consistent
with previous experience with high-dose IL-2 therapy. These
data suggest that the combination was tolerated, and further
investigation is warranted to better define the response rate of
this combination, but not with high dose IPI. Notably, in the
previous study by Maker et al. (8), the response rate was higher,
despite using very low doses of IPI, suggesting that high dose IPI
(10 mg/kg) does not improve outcomes with IL-2 and should not
be tested further.
Our data suggest that response to combination high-dose
IPI and high-dose IL-2 is associated with markers of antigen
presenting machinery regulated by the ratio of non-classical
MHC-II proteins HLA-DM and HLA-DO. HLA-DM catalyzes
the peptide loading of MHC-II molecules. HLA-DM is negatively
regulated by HLA-DO; thus, a high HLA-DM:HLA-DO indicates
that the antigen presentation machinery is optimally poised
for peptide loading. Serial sampling of peripheral blood in
patients treated with combination high-dose IPI and high-dose
IL-2 identified that patients with decreased tumor burden had
a higher ratio of the non-classical MHC-II HLA-DM:HLA-
DO protein levels. HLA-DM promotes peptide loading into
the MHC-II pocket by catalyzing the removal of CLIP, and
HLA-DM is negatively regulated by HLA-DO. Thus, a high
HLA-DM:HLA-DO ratio indicates that the antigen presentation
machinery is poised for peptide loading (14, 15). The importance
of MHC proteins as predictve biomarkers is demonstrated in
a previous report in which MHC-I expression (although not
MHC-II expression) was show to be associated with favorable
response to ipilimumab (18); thus, our findings support the
notions that effective antigen presentation is a key component
FIGURE 3 | Peripheral blood HLA-DM:HLA-DO ratio and serum granzyme B are elevated in patients with decreased tumor burden following treatment with high-dose
IPI and high-dose IL-2. The left panel shows the fold-change in HLA-DM:HLA-DO expression measured by flow cytometry within peripheral blood B cells (CD45+
CD19+ MHC-II+) of patients with an increase in tumor burden (n = 6) vs. patients with a decrease in tumor burden (n = 3). The right panel shows the fold-change in
serum granzyme B over baseline (week 1) in patients with an increase in tumor burden (n = 6) vs. patients with a decrease in tumor burden (n = 3). Two-way ANOVA
with Bonferroni correction; *P < 0.05 and **P < 0.01. Error bars represent S.E.M.
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of the mechanism of action of checkpoint blockade, and MHC
protiens are emerging as predictive biomarkers. In addition,
we observed that activated lymphocyes with increased cytolytic
potential as demonstrated by enhanced granzyme B expression
were associated with favorable response.
Our experience highlights potential opporunites and
challenges in conducting such clinical trials in the contemporary
period. According to a prospectively-collected registry study,
high-dose IL-2 retains its efficacy in the post-anti-PD-1
monotherapy setting (7); therefore, safety and activity with this
combination in the setting of disease progression following
anti-PD-1 treatment may inform the development of novel
formulations of IL-2 as salvage therapies. In particular, the use of
modified IL-2 molecules designed to promote effector CD8+ T
cell responses and limit CD4+ regulatory T cell responses may
offer a better strategy for IL-2-based combinations (19). Future
studies of IPI and IL-2 should utilize low doses of IPI and most
likely will incorporate novel IL-2-based compounds.
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